ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Saturday, November 7, 2020

9:00AM-11:00AM: Abstract Number: 0731

Comparing S100 Proteins and Cytokine Levels in Tears Based on Uveitis Activity Laterality in Children with JIA-associated Uveitis and Non-JIA-U

Pediatric Rheumatology – Clinical Poster II: JIA

9:00AM-11:00AM: Abstract Number: 0884

Comparison of Disease Control Thresholds in Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 0797

Comparison of the Efficacy and Safety of Janus Kinase Inhibitors and DMARDs in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis

RA – Treatments Poster II: Comparative Effectiveness, Biosimilars, Adherence & the Real World

9:00AM-11:00AM: Abstract Number: 0627

Complications of COVID-19 Infection in Patients with Rheumatic Disease: A Case Series

Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 0741

Constitutive Inhibitor Kappa B (IκB) Kinase 2 (IKK2) Activation Induces an Inflammatory State in Fibroblast-Like Synoviocytes

RA – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 0707

Contribution of NOTUM and Glypicans to the Development of Osteoarthritis

Osteoarthritis & Joint Biology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 0616

Correlation Between Disease Activity and Perceived Economic Barriers to Care in a Population of African American Women with Systemic Lupus Erythematosus

Health Services Research Poster

9:00AM-11:00AM: Abstract Number: 0583

Cost of Illness in Patients with Psoriasis and Psoriatic Arthritis

Health Services Research Poster

9:00AM-11:00AM: Abstract Number: 0585

Cost-effectiveness of Motivational Counselling and SMS-reminders on Daily Sitting Time in Patients with Rheumatoid Arthritis

Health Services Research Poster

9:00AM-11:00AM: Abstract Number: 0629

COVID-19 Among Patients with Immune-mediated Inflammatory Diseases: A Descriptive Study

Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 0640

Covid-19 and Rheumatic and Musculoskeletal Disease Patients: Infection Rates, Attitudes and Medication Adherence

Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 0642

COVID-19 Infection in Rheumatologic Patients on Treatment with Targeted Therapies

Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 0923

Criteria for the Diagnosis of Raynaud’s Phenomenon – Do They Recognize the Same Patients?

Systemic Sclerosis & Related Disorders – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 0623

Cytokine Storm: Outcomes in SARS-CoV-2 Patients Treated with Biologics in a Rheumatology Cohort

Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 0918

Decline in Forced Vital Capacity in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) with and Without Gastroesophageal Reflux Disease: Further Analyses of the SENSCIS Trial

Systemic Sclerosis & Related Disorders – Clinical Poster II

«Previous Page
1
…
4
5
6
7
8
…
32
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].